All In Biotech

Drug Trial Radar · NCT04621136

PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity

Last checked: Nov 19, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Nov 1, 2020

Primary completion

Nov 30, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Kyushu UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 4 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm phase I/II trial to evaluate the safety and efficacy of Rho-associated protein kinase(ROCK) inhibitor Ripasudil eye drops for preterm infants with Retinopathy of Prematurity(ROP).

Conditions

  • Retinopathy of Prematurity

Interventions

  • Ripasudil ophthalmic solution 0.4%Drug

    Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin. Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with Adverse Events(AEs) and Adverse Drug Reactions(ADRs)Time frame: throughout the study duration(up to week16)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Kyushu University Hospital

    Fukuoka, Japan

  • University Hospital of Occupational and Environmental Health

    Kitakyushu, Fukuoka, Japan

  • Yamaguchi University Hospital

    Ube, Yamaguchi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.